Bone marrow involvement in breast cancer: a retrospective cohort study.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
16 cases (32%) and included luminal converting into triple negative BC (n = 6; 37.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Bone marrow metastases indicate a poor prognosis. The high rate of receptor conversion highlights the importance of re-evaluating tumor biology after BC progression which may increase the scope of systemic treatment options and improve the prognosis.
[PURPOSE] The incidence of bone marrow metastases is a rarely described manifestation of metastatic breast cancer (BC).
- 표본수 (n) 47
- p-value p = 0.023
- p-value p < 0.001
- 95% CI 6.3 - 14.9
APA
Sigorski D, Wilk M, et al. (2026). Bone marrow involvement in breast cancer: a retrospective cohort study.. Advances in medical sciences, 71(1), 130-137. https://doi.org/10.1016/j.advms.2026.03.006
MLA
Sigorski D, et al.. "Bone marrow involvement in breast cancer: a retrospective cohort study.." Advances in medical sciences, vol. 71, no. 1, 2026, pp. 130-137.
PMID
41895475
Abstract
[PURPOSE] The incidence of bone marrow metastases is a rarely described manifestation of metastatic breast cancer (BC).
[MATERIAL AND METHODS] Clinical, laboratory and histopathological data were retrospectively analyzed in 50 women with histopathologically confirmed BC metastasis.
[RESULTS] The median age was 68.3 years, and 60% of patients had an ECOG performance status of 0-1. Most cases were BC of no special type (n = 47; 94%), primary in 70% (n = 35). The luminal Human Epidermal Growth Factor Receptor 2 (HER2) - was the predominant biological subtype (n = 35; 70%). The most common indications for trephine biopsy were anemia and thrombocytopenia. Synchronous bone metastases occurred in most patients. Biological type 4conversion was seen in 16 cases (32%) and included luminal converting into triple negative BC (n = 6; 37.5%) and luminal HER2+ into luminal HER2- BC (n = 3; 18.75%). The median of overall survival (OS) was 9.2 months (95% CI: 6.3 - 14.9). High lactate dehydrogenase level (p = 0.023) and thrombocytopenia (p < 0.001) correlated with a shorter median OS. In multivariate analysis, low levels of platelets correlated with a lower median OS (p < 0.001). A positive correlation occurred between lymphocytes (p < 0.001), monocytes (p < 0.001) and the percentage of bone marrow infiltration. Higher neutrophil-to-lymphocyte ratio was associated with shorter survival (p = 0.02).
[CONCLUSIONS] Bone marrow metastases indicate a poor prognosis. The high rate of receptor conversion highlights the importance of re-evaluating tumor biology after BC progression which may increase the scope of systemic treatment options and improve the prognosis.
[MATERIAL AND METHODS] Clinical, laboratory and histopathological data were retrospectively analyzed in 50 women with histopathologically confirmed BC metastasis.
[RESULTS] The median age was 68.3 years, and 60% of patients had an ECOG performance status of 0-1. Most cases were BC of no special type (n = 47; 94%), primary in 70% (n = 35). The luminal Human Epidermal Growth Factor Receptor 2 (HER2) - was the predominant biological subtype (n = 35; 70%). The most common indications for trephine biopsy were anemia and thrombocytopenia. Synchronous bone metastases occurred in most patients. Biological type 4conversion was seen in 16 cases (32%) and included luminal converting into triple negative BC (n = 6; 37.5%) and luminal HER2+ into luminal HER2- BC (n = 3; 18.75%). The median of overall survival (OS) was 9.2 months (95% CI: 6.3 - 14.9). High lactate dehydrogenase level (p = 0.023) and thrombocytopenia (p < 0.001) correlated with a shorter median OS. In multivariate analysis, low levels of platelets correlated with a lower median OS (p < 0.001). A positive correlation occurred between lymphocytes (p < 0.001), monocytes (p < 0.001) and the percentage of bone marrow infiltration. Higher neutrophil-to-lymphocyte ratio was associated with shorter survival (p = 0.02).
[CONCLUSIONS] Bone marrow metastases indicate a poor prognosis. The high rate of receptor conversion highlights the importance of re-evaluating tumor biology after BC progression which may increase the scope of systemic treatment options and improve the prognosis.